Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Henzi BC, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Putananickal N, Stimpson G; North Star Consortium; Amthor H, Childs AM, Deconinck N, de Groot I, Horrocks I, Houwen-van Opstal S, Laugel V, Lopez Lobato M, Madruga Garrido M, Nascimento Osorio A, Schara-Schmidt U, Spinty S, von Moers A, Lawrence F, Hafner P, Dorchies OM, Fischer D. Henzi BC, et al. Lancet Neurol. 2023 Oct;22(10):890-899. doi: 10.1016/S1474-4422(23)00285-5. Lancet Neurol. 2023. PMID: 37739572 Clinical Trial.
Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
Stimpson G, Ridout D, Wolfe A, Milev E, O'Reilly E, Manzur A, Sarkozy A, Muntoni F, Cole TJ, Baranello G; NorthStar Network. Stimpson G, et al. J Neuromuscul Dis. 2024;11(1):153-166. doi: 10.3233/JND-230159. J Neuromuscul Dis. 2024. PMID: 37980680 Free PMC article.
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
Wolfe A, Stimpson G, Ramsey D, Coratti G, Dunaway Young S, Mayhew A, Pane M, Rohwer A, Muni Lofra R, Duong T, O'Reilly E, Milev E, Civitello M, Sansone VA, D'Amico A, Bertini E, Messina S, Bruno C, Albamonte E, Mazzone E, Main M, Montes J, Glanzman AM, Zolkipli-Cunningham Z, Pasternak A, Marini-Bettolo C, Day JW, Darras BT, De Vivo DC, Baranello G, Scoto M, Finkel RS, Mercuri E, Muntoni F; international SMA consortium (iSMAc). Wolfe A, et al. J Neuromuscul Dis. 2024;11(3):665-677. doi: 10.3233/JND-230211. J Neuromuscul Dis. 2024. PMID: 38427497 Free PMC article.
Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec - The SMA REACH UK network experience.
Wolfe A, Sheehan J, Schofield A, Cranney H, O'Reilly E, Stimpson G, Andrews A, Vanegas M, Lucas J, Scoto M, Gowda V, Wraige E, Jungbluth H; SMA REACH UK network. Wolfe A, et al. Neuromuscul Disord. 2024 Nov;44:104451. doi: 10.1016/j.nmd.2024.104451. Epub 2024 Sep 15. Neuromuscul Disord. 2024. PMID: 39378752
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.
Sharib J, Rhodin KE, Liu A, McIntyre S, Bartholomew A, Masoud S, DeLaura I, Kemeny NE, Cercek A, Harding JJ, O'Reilly EM, Abou-Alfa GK, Reidy-Lagunes D, Connell LC, Dika IE, Balachandran VP, Drebin J, Soares KC, Wei AC, Kingham TP, D'Angelica MI, Uronis H, Strickler J, Hsu SD, Morse M, Zani S, Allen PJ, Jarnagin WR, Lidsky ME. Sharib J, et al. Among authors: o reilly em. Ann Surg Oncol. 2025 Jan 18. doi: 10.1245/s10434-024-16799-0. Online ahead of print. Ann Surg Oncol. 2025. PMID: 39827317
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival.
Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, Zucker A, Fong C, Mehine M, Nguyen B, Basturk O, Balogun F, Kelsen DP, Brannon AR, Mandelker D, Vakiani E, Park W, Yu KH, Stadler ZK, Schattner MA, Jarnagin WR, Wei AC, Chakravarty D, Capanu M, Schultz N, Berger MF, Iacobuzio-Donahue CA, Bandlamudi C, O'Reilly EM. Varghese AM, et al. Among authors: o reilly em. Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03362-3. Online ahead of print. Nat Med. 2025. PMID: 39753968
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer.
Schleimer LE, Aviki E, Kalvin HL, Magnin J, Sokolowski SS, Kingham TP, O'Reilly EM, Varghese AM, Soares KC, Drebin J, D'Angelica MI, Jarnagin WR, Gonen M, Thom B, Wei AC. Schleimer LE, et al. Among authors: o reilly em. JCO Oncol Pract. 2024 Dec 20:OP2400528. doi: 10.1200/OP-24-00528. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39705655
Survival of Patients with Resected Microsatellite Instability-High, Mismatch Repair Deficient, and Lynch Syndrome-Associated Pancreatic Ductal Adenocarcinomas.
Eikenboom EL, Nasar N, Seier K, Gönen M, Spaander MCW, O'Reilly EM, Jarnagin WR, Drebin J, D'Angelica MI, Kingham TP, Balachandran VP, Soares KC, Wagner A, Wei AC. Eikenboom EL, et al. Among authors: o reilly em. Ann Surg Oncol. 2024 Dec 10. doi: 10.1245/s10434-024-16621-x. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39656390
706 results